

Ekaterina Gibiansky
Pharmacometric Publications
1994 - 2002

- B.R. Yacyshyn, W.Y. Chey, J. Goff, B. Salzberg, R. Baerg, A.L. Buchman, J. Tami, R. Yu, **E. Gibiansky**, W.R. Shanahan. Double-blind, placebo-controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302) in active, steroid-dependent Crohn's disease. *Gut* 51:30-36 (2002)
- C. Garnett, B. Birmingham, **E. Gibiansky**, S. Rubin, P. Plourde. Population Pharmacokinetics of Tamoxifen In Pediatric females With McCune-Albright Syndrome (MAS). *Pharm. Res.* (2002)
- J.S. Barrett, **E. Gibiansky**, R.D. Hull, A. Planes, H. Pentikis, J.W. Hainer, T.A. Hua, M. Gastonguay. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. *Int J Clin Pharmacol Ther.* 2001 Oct;39(10):431-46.
- L. Gibiansky, **E. Gibiansky**, R.Z. Yu, and R.S. Geary, Population Pharmacokinetics of ISIS 2302, *Clin Pharm Ther*, 69(2):27, 2001
- E. Gibiansky**, L. Gibiansky, S. Bramer. Comparison of nonmem, bootstrap, jackknife and profiling parameter estimates and confidence intervals for the aripiprazole population PK model. *Pharm. Res.* (2001)
- L. Gibiansky, **E. Gibiansky**. Parameter estimates and confidence intervals for population PK model. *Pharm. Res.* (2001)
- E. Gibiansky**, T. Ludden, S. Mallikaarjun, A. Corey, X. Chen, D. Salazar, S. Bramer. Population analysis of efficacy and safety of aripiprazole. *Pharm. Res.* (2001)
- L. Gibiansky, **E. Gibiansky**, R.Z. Yu, and R.S. Geary. ISIS 2302: validation of the population PK model and PK/PD analysis. *Pharm. Res.* (2001)
- X. Chen, **E. Gibiansky**, S. Mallikaarjun, D.E. Salazar, T. Ludden, S.L. Bramer. Population Pharmacokinetic Analysis Of Aripiprazole. *Pharm. Res.* (2001)
- E. Gibiansky**, L. Gibiansky T. Jaworski, and M. Grindel, Population Pharmacokinetics of Poloxamer 188, *Clin Pharm Ther*, 67(2), 2000.
- Gibiansky E**, Barrett JS, Pentikis HS. A population pharmacokinetic analysis of anti-xa activity of tinzaparin from a phase III clinical study. *Pharm. Res.* 16(11): (1999)
- Gibiansky E**, Mallikaarjun S, Chen X, and Bramer S. Covariate selection via model-free population pharmacokinetics. *Eur. J. Pharm. Sci.* 8(2): vii-viii (1999)
- Nedelman JR, **Gibiansky E**, Cramer J, Kovarik J, Meligeni J, and Robbins B. Multiple-Dose pharmacokinetics of a long half-life drug: Contributions of mathematical modeling. *Eur. J. Drug. Metab. and Pharmacokin.* 22:179-184 (1997)
- Nedelman J, Cramer JA, Robbins B, **Gibiansky E**, Chang CT, Gareffa S, Cohen A, and Meligeni J. The Effect of Food on the Pharmacokinetics of Multiple Dose Terbinafine in Young and Elderly Healthy Subjects. *J. Biopharm. and Drug Disp.*, 18:2, 127-138 (1997)
- Gibiansky E**, Mallikaarjun S, and Bramer S. Nonparametric population pharmacokinetics of cilostazol. *Pharm. Res.* 14(11):515 (1997)
- Nedelman JR, **Gibiansky E**. The variance of a better AUC Estimator for Sparse, Destructive Sampling in Toxicokinetics. *J.Pharm.Sci.* 85(8):884-886 (1996)
- Pai SM, Nedelman JR, Hajian G, **Gibiansky E**, and Batra VK. Performance of Bailer's method for AUC confidence intervals from sparse non-normally distributed drug concentrations in toxicokinetic studies. *Pharm. Res.* 13(9):1280-1282 (1996)

- Nedelman JR, **Gibiansky E**, Robbins BA, Cramer JA, Riefler JF, Lin T, and Meligeni JA. Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. *J. Clin. Pharmacol.* 36:451-461 (1996)
- Gibiansky E**. Application of simulation to study design: multiple-dose pharmacokinetics of long half-life drug. *Proceedings of the SCS Multiconference on Simulation in Medical Sciences.* 150-153 (1996).
- Nedelman JR, Karara AH, Chang CT, **Gibiansky E**, McDonald S, and Robinson WT. Inferring systemic exposure from a pharmacokinetic screen: model-free and model-based approaches. *Stat. In Med.* 14:955-968 (1995).
- Gibiansky E**. Multiple minima: phenomena of the data or a drawback of the method? Comparison of SAS/IML nonlinear optimization routines. *Proceedings of 8th NorthEast SAS Users Group Conference.* 621-624(1995).
- Nedelman JR, **Gibiansky E**, Lau DT. Applying Bailer's method for AUC confidence intervals to sparse sampling. *Pharm. Res.* 12:124-128 (1995).
- Nedelman JR, **Gibiansky E**, Tse FL, and Babiuk C. Assessing drug exposure in rodent toxicity studies without satellite animals. *J. Pharmacokin. Biopharm.* 21:323-334 (1994).
- E. Gibiansky**. Best initial values for nonlinear estimation: stripping algorithm implemented as SAS/IML routine. *Proceedings of the Northeast SAS Users Group Meeting.* 559-563 (1994).